Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II-Reference-Cited by-同舟云学术

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II

Published:1997-06 Issue:12 Volume:53 Page:1843-1853
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Hasinoff Brian B.,Kuschak Theodore I.,Creighton Andrew M.,Fattman Cheryl L.,Allan William P.,Thampatty Padmakumari,Yalowich Jack C.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference47 articles.

1. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors;Ishida;Cancer Res,1991

2. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane);Hasinoff;Biochem Pharmacol,1995

3. Phase II study: Treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine);Ohno;J Nad Cancer Inst,1992

4. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp;Roca,1994

5. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Sehested;Biochem Pharmacol,1993

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational assessment of the reactivity and pharmaceutical potential of novel triazole derivatives: An approach combining DFT calculations, molecular dynamics simulations, and molecular docking;Arabian Journal of Chemistry;2024-01

2. In vivo partial cellular reprogramming enhances liver plasticity and regeneration;Cell Reports;2022-04

3. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition;Toxicology and Applied Pharmacology;2020-07

4. Resveratrol: A novel type of topoisomerase II inhibitor;Journal of Biological Chemistry;2017-12

5. Docking and DFT Studies to explore the Topoisomerase II ATP Pocket employing 3-Substituted 2,6-Piperazindiones for drug design;Molecular Simulation;2012-11